Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Biotech Services HoldingsHKSE:08037 -1.54%19 Median PS Value is HK$0.28 as of Jul. 25, 2026, which is 100% below its 10-year median of 3.01. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks worse than 93.18% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for China Biotech Services Holdings's Median PS Value or its related term are showing as below:
HKSE:08037'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26 Med: 3.01 Max: 13.93
Current: 2.29
During the past 13 years, the highest Price to Median PS Value of China Biotech Services Holdings was 13.93. The lowest was 0.26. And the median was 3.01.
HKSE:08037's Price-to-Median-PS-Value is ranked worse than 93.18% of 88
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.865
vs HKSE:08037: 2.29
China Biotech Services Holdings (HKSE:08037) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
China Biotech Services Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.64
/
0.28
=
2.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings Median PS Value Related Terms
China Biotech Services Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings Median PS Value Chart
HKSE:08037 vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.7333.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Biotech Services Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.075.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings (HKSE:08037) has a Median PS Value of HK$0.28 as of Jul. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Biotech Services Holdings and its competitors. This is 91% below median its historical median of 3.01. Over the past decade, China Biotech Services Holdings' Median PS Value has ranged from 0.26 to 13.93. According to the industry distribution chart, China Biotech Services Holdings ranks #82 out of 88 companies in the Medical Diagnostics & Research industry, placing it in the top 93.2%.
Is China Biotech Services Holdings' Median PS Value too high?
China Biotech Services Holdings' current Median PS Value of HK$0.28 is 91% below median its 10-year median of 3.01. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 13.93. Based on the distribution chart, China Biotech Services Holdings ranks #82 out of 88 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #82 out of 88 companies for Median PS Value. This places China Biotech Services Holdings in the lower half of its industry. The industry median Median PS Value is 0.87. Historically, China Biotech Services Holdings' own Median PS Value has ranged from 0.26 to 13.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.87, based on 88 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Median PS Value is HK$0.28, which is 91% below median its own 10-year median of 3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Median PS Value is HK$0.28, which is 91% below median its 10-year median of 3.01. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Median PS Value is HK$0.28 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
Median PS Value: HK$0.28 (91% below median its 10-year median of 3.01)
GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Business Description
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
